PAIGE.AI, Inc. Overview
Pro stress-test →PAIGE.AI, Inc. is a New York-based company founded in 2018 that develops AI applications and foundation models for cancer diagnostics. The company provides tissue-based AI-assisted applications to support cancer detection, subtyping, and molecular biomarker discovery. PAIGE was acquired by Tempus AI in August 2025.
Strategic Profile
Pro stress-test →PAIGE is the first company to receive FDA approval for a clinical AI application in digital pathology. The company has built its foundation on a proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated. Through its acquisition by Tempus, PAIGE enables growth of Tempus's dataset, expansion of technical team capability, and establishes a strong footprint in digital pathology with an industry-leading technology portfolio.
Competitive Landscape
Pro stress-test →PAIGE's top competitors include PathAI and Ibex. Other competitors include CureMetrix, Boreal Genomics, Ibex Medical Analytics, Tempus AI, and Inspirata. PAIGE differentiates through its 7M-slide proprietary dataset, first FDA-cleared pathology AI, and foundation models trained on million-scale clinical slides. Strategic integration into Tempus's precision medicine platform provides distribution and data advantages.
Industry Context
PAIGE.AI, Inc. operates in Clinical AI & Drug Discovery.
Key facts
Founded: 2018 · Headquarters: New York, US · Employees: 39